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Abstract
New treatments are needed for neglected tropical diseases (NTDs) such as Human African
trypanosomiasis (HAT), Chagas disease, and schistosomiasis. Through a whole organism
high-throughput screening campaign, we previously identified 797 human kinase inhibitors
that grouped into 59 structural clusters and showed activity against T. brucei, the causative
agent of HAT. We herein report the results of further investigation of one of these clusters
consisting of substituted isatin derivatives, focusing on establishing structure-activity and
-property relationship scope. We also describe their in vitro absorption, distribution, metabo-
lism, and excretion (ADME) properties. For one isatin, NEU-4391, which offered the best
activity-property profile, pharmacokinetic parameters were measured in mice.
Author summary
Human African trypanosomiasis (HAT) is a parasitic disease prevalent in sub-Saharan
Africa. Current treatments cause severe toxicity, are difficult to administer, and are sus-
ceptible to resistance. In order to quickly discover new leads for HAT drug discovery, we
screened human kinase inhibitors against Trypanosoma brucei, the parasite that causes
HAT, and discovered several hundred compounds that demonstrated antiparasitic activ-
ity. In this paper, we present the results of medicinal chemistry follow-up work on a group
of compounds known as isatins.
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Introduction
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a parasitic disease
endemic in 36 African countries. Along with 19 other indications, HAT is designated as a
neglected tropical disease (NTD) by the World Health Organization [1, 2]. Although there
were fewer than 3,000 reported cases in 2015, the current burden of HAT amounts to 390,100
disability-adjusted life years [2, 3]. Caused by two subspecies of the parasite Trypanosoma bru-
cei (T. b. gambiense and T. b. rhodesiense), HAT proceeds in two stages following initial infec-
tion via the bite of a tsetse fly. In the first stage, the parasite is present in the blood and lymph
systems of the patient and causes mild, flu-like symptoms. In the second stage, the parasite
crosses the blood-brain barrier (BBB) into the central nervous system (CNS) and causes a vari-
ety of neurological and behavioral changes, including disrupted sleeping patterns [2]. HAT is
100% fatal if left untreated, and the available drugs are associated with safety concerns, suscep-
tibility to resistance, and lack of efficacy against all T. brucei subspecies and stages of the dis-
ease [4]. Currently, there are two new compounds for HAT in clinical trials: fexinidazole and
acoziborole [5, 6]. However, given the high failure rate of compounds in clinical trials [7], it is
prudent to continue to search for compounds to fill the drug discovery pipeline for HAT.
It has been shown by others that T. brucei expresses essential kinases [8], and furthermore,
by our group, that human kinase inhibitors can be successfully re-optimized against these par-
asites [9–11]. As part of a lead repurposing strategy [12], we tested over 40,000 human kinase
inhibitors in a high-throughput screen (HTS) against T. b. brucei [13]. This initial screening
set was narrowed to 797 compounds with T. b. brucei pEC50 >6 and>100× selectivity over
HepG2 cells. These final hits were then clustered based on structural similarity. We herein
report the development of structure-activity and structure-property relationships (SAR and
SPR) for one of these clusters.
The compounds NEU-1183, NEU-1184, and NEU-1185 (Fig 1) are representatives of a
cluster of isatinoids that were identified in our kinase-targeted HTS as inhibitors of T. brucei
growth. Various measured and computed properties of this cluster are shown in Table 1,
along with our targeted values for each property. In addition to physicochemical properties
such as clogP (calculated partition coefficient) and topological polar surface area (TPSA), we
also considered metrics such as lipophilic ligand efficiency (LLE) [14] and CNS multi-parame-
ter optimization (CNS-MPO) scores [15] when evaluating compounds. Overall, the isatinoids
had good to excellent physicochemical properties that made them an attractive starting point
for further development. Their generally low clogP and high LLE values suggested that
Fig 1. Structures of NEU-1183, -1184, and -1185.
https://doi.org/10.1371/journal.pntd.0007129.g001
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expansion of the structure would be tolerated from a property standpoint if necessary, and
their high CNS-MPO scores indicated a likelihood of brain penetration (necessary for treat-
ment of stage 2 infection). We therefore looked at ways to improve the potency and aqueous
solubility of these compounds while maintaining their desirable physicochemical profile.
Methods
Bioactivity assays
In order to determine the T. b. brucei EC50 values, 4 μL per well from compound master plates
were dispensed into a new plate and 96 μL of HMI-9 per well were added to generate a 4%
DMSO intermediate plate. Mid-log phase growth T. b. brucei was diluted to a working cell
density of 2,750 cells/mL and 90 μL/well dispensed into 96-well flat-bottom transparent assay
plates (Nunc). Ten μL/well from intermediate plates were added. The final top concentration
of compounds was 40 μM in 0.4% DMSO per well.
Assay plates were incubated for 72 h at 37˚C and 5% CO2. Four hours prior to the end of
the incubation, 20 μL of a 440 μM resazurin solution in prewarmed HMI-9 was added to each
well and incubated for another 4 h. Fluorescence was then measured in an Infinite F200 plate
reader (Tecan) at 550 nm (excitation filter) and 590 nm (emission filter). A 4-parameter equa-
tion was employed to fit the dose-response curves and determine of EC50 using the SigmaPlot
13.0 software. Assays were performed in duplicate at least twice, to achieve a minimal n = 3
per dose response.
Detailed protocols for rate of action assays, Trypanosoma cruzi and Leishmania donovani
EC50 assays, MRC5 and THP-1 cytotoxicity assays, and Schistosoma mansoni assays are pro-
vided in S2 Text.
Pharmacokinetics protocols
NEU-4391 was administered intraperitoneally (IP) to two groups of female NMRI mice
(Group 1 n = 3; Group 2 n = 6). The compound was prepared in 1% (v/v) DMSO:99% (v/v)
20% (w/v) sulfobutyl ether-beta-cyclodextrin (SBE-β-CD) (Captisol) in water and the dosing
volume was 10 mL/kg for a total dose of 10 mg/kg. Food and tap water were available ad libi-
tum. Following IP dosing, Group 1 blood samples were collected from the tail vein into capil-
lary tubes containing K2EDTA at the following time-points: 0.0833, 0.25, 0.5, 1, 2, 4, 6, 8 and
24 h.
Table 1. Targeted values, cluster average, and individual values for the physicochemical properties of interest of NEU-1183, NEU-1184 and NEU-1185. Data from
original HTS [13]. nd = no data.
Targeted Value Cluster Average NEU-1183 NEU-1184 NEU-1185
T.b.b. pEC50 �7.0 7.0 7.6 7.1 6.4
HepG2 pTC50
a <5.0 4.3 5.0 4.0 4.0
cLogP �3 1.1 2.3 0.52 0.41
LLE �5 5.9 5.3 6.5 6.0
TPSA (Å2) 40<x�90 127 114 127 140
MWt (Da) �360 374 370 367 383
CNS-MPO Score �3 4.3 4.2 4.5 4.1
Kinetic aq. solubility (μM) >10 nd <5 7.7 18
aTC50 = 50% toxic concentration.
https://doi.org/10.1371/journal.pntd.0007129.t001
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In order to obtain simultaneous blood and brain samples, Group 2 mice were placed under
terminal anaesthetic (isoflurane) and blood samples (0.3 mL) collected from the retro-orbital
sinus into K2EDTA tubes at 0.5 h (n = 3) and 4 h (n = 3) after compound administration.
Immediately following blood sample collection, death was confirmed by cervical dislocation
and the brain removed. Aliquots of each blood sample were diluted in an equal volume of
water. Mouse brain samples were weighed, water was added at a 1/2 (w/v) ratio (brain/water),
and then homogenized. Both blood and brain samples were stored -80˚C until analysis.
Diluted blood and brain homogenates were processed under standard liquid-liquid extrac-
tion procedures using acetonitrile containing an internal standard (Nifedipine) and analyzed
by LC-MS/MS. Non-compartmental analysis was performed using the Phoenix pharmacoki-
netic software version 1.4 (Certara) and Cmax, tmax, AUClast, AUC, and t1/2 were estimated.
Ethics statement
All animal studies were ethically reviewed and carried out in accordance with Animals (Scien-
tific Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Ani-
mals. This work was performed at Charles River Laboratories, Edinburgh Ltd. under the UK
Home Office Project Procedure Project License No. PPL 70/8781: Drug Metabolism and Phar-
macokinetics, Protocol Reference Number 1 and 6.
Chemistry
All sulfonamide-replacement analogs were synthesized by first preparing the requisite hydra-
zine from an aryl chloride or bromide, and subsequently coupling with isatin by stirring in
methanol at room temperature. A mixture of isomers was isolated by vacuum filtration and
further resolved by purification or recrystallization. All compounds tested had a purity of
>95% as measured by LCMS. Details regarding compound syntheses and characterization are
provided in S1 Text.
Results
In addition to the three compounds shown in Table 1, analogs with substituents at the C4, C5,
and C6 (R3, R2, and R1, respectively) were obtained from the GSK compound collection and
tested against T. brucei; the biological activity of these compounds is presented in Table 2 (the
general structure of analogs presented is shown in Fig 2). The most potent of these compounds
was NEU-5469, with methyl groups at R1 and R3 and a hydroxy group at R2. Changing R3 to a
chloro, as in NEU-5485, resulted in a log unit drop in potency; further changing R1 to an iso-
propyl group (NEU-5455) resulted in another drop in potency of over half a log unit. Further
exploration of the R3 substituent showed that in general, small alkyl substituents were best in
terms of both potency and LLE. The ethyl (NEU-5489), isopropyl (NEU-5491), isobutyl
(NEU-5487), and isobutylene (NEU-1183) were approximately equipotent, although NEU-
1183 has a slightly improved LLE due to its low clogP (2.2 versus NEU-5487’s 3.4). Amides
(NEU-5460) and larger substituents (NEU-5492 and NEU-5493) at this position generally
resulted in less potent compounds as compared to the alkyl substituents. Analogs substituted
at both R2 and R3 (NEU-5464) were significantly more potent than analogs substituted only at
R2 (NEU-2319). Comparing NEU-5464 to NEU-5479, the methyl substituent at R2 results in a
loss of potency of almost half a log unit as compared to the chlorine, showing that in this case,
chlorine does not act as a bioisostere for a methyl group. Aromatic fused ring systems, such as
those of NEU-1184 and NEU-5456, were more potent than the aliphatic ring of NEU-5459.
As a general measure of mammalian cell toxicity, compounds were tested against either
Evaluation of isatinoids as anti-trypanosomal agents
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HepG2 (original hits) or MRC5 (follow-up compounds) cell lines; no analogs showed signifi-
cant toxicity against either cell type.
Given the established SAR around the isatin core, we decided to focus further efforts on
replacing the sulfonamide moiety. Because of easier synthetic accessibility, initial analogs were
synthesized without any substituents on the core by first making the requisite hydrazine 2
from the aryl halide 1 (X = Br or Cl) and coupling with isatin as shown in Fig 3. The double
bond geometry of 3 was confirmed by X-ray crystallography (S1 Fig; CCDC ID 1865900) to be
the (Z) isomer as shown in Fig 3, where an intramolecular hydrogen bond is formed between
Table 2. Potency, LLE, and toxicity data for substituted-core analogs.
R1 R2 R3 T.b.b. pEC50 T.b.b. LLE pTC50
NEU-1183� -H -H -CHC(CH3)2 7.5 5.3 5.0
a
NEU-1185� -H 5-oxazole -H 6.4 6.0 <4.0a
NEU-2319 -H -Cl -H 6.0 3.7 <5.0b
NEU-5455 -iPr -OH -Cl 6.4 3.2 <5.0b
NEU-5460 -H -H -CONH2 6.2 5.7 <5.0
b
NEU-5464 -H -Cl -CH3 7.3 5.2 <5.0
b
NEU-5469 -CH3 -OH -CH3 8.2 5.8 <5.0
b
NEU-5470 -Et -H -H 6.1 3.9 <5.0b
NEU-5479 -H -CH3 -CH3 6.9 4.2 <5.0
b
NEU-5485 -CH3 -OH -Cl 7.1 4.6 <5.0
b
NEU-5487 -H -H -CH2CH(CH3)2 7.4 4.0 <5.0
b
NEU-5489 -H -H -Et 7.5 4.9 <5.0b
NEU-5491 -H -H -iPr 7.6 4.7 <5.0b
NEU-5492 -H -H -CH2cyBu 6.9 3.6 <5.0
b
NEU-5493 -H -H -CH2CH2-4-hydroxybenzene 6.0 2.1 <5.1b
NEU-1184� See Fig 2 7.1 6.4 <4.0a
NEU-5456 See Fig 2 7.4 5.5 <5.0b
NEU-5459 See Fig 2 6.1 4.9 <5.0b
aHepG2 toxicity
bMRC5 toxicity.
�Data from original HTS [13]. All experimental error was within ±0.20 log units.
https://doi.org/10.1371/journal.pntd.0007129.t002
Fig 2. General structure of analogs presented in Table 2 as well as structures of NEU-1184, -5456, and -5459.
https://doi.org/10.1371/journal.pntd.0007129.g002
Evaluation of isatinoids as anti-trypanosomal agents
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007129 February 8, 2019 5 / 12
the amide carbonyl and the hydrazone -NH. Later, analogs with an isobutylene substituent at
R3 were also synthesized; this core was constructed via a Suzuki coupling with 4-bromoisatin 4
and boronic ester 5 as shown in Fig 3.
Additionally, we noted the structural similarity of this chemotype to hesperadin, an investi-
gational human Aurora kinase inhibitor that we previously demonstrated as active against T.
brucei (Fig 4) [16]. With this in mind, NEU-4893 was designed as a crossover analog. Synthe-
sis, shown in Fig 4, began with a reductive amination between 4-chlorobenzaldehyde 7 and
piperidine, followed by displacement of the chloride under Buchwald conditions with boc-
hydrazine to yield 9. This compound was then deprotected using HCl to yield the HCl salt 10,
which was coupled with isatin to yield the final compound NEU-4893.
The biological activities of the sulfonamide replacement analogs are shown in Table 3 (the
general structure of analogs presented is shown in Fig 5). The removal of the olefin at R3
resulted in the loss of nearly two log units of potency against T. brucei, illustrated by NEU-
2115. Replacement of the sulfonamide invariably resulted in a loss of potency as compared to
the unsubstituted primary sulfonamide NEU-2115, demonstrating that this moiety is critical
for activity. Tuning the electronics of the aryl ring at R4 had a modest effect on potency; where
the electron-rich NEU-2114 was approximately equipotent to the unsubstituted NEU-2116,
the electron-poor NEU-2117 lost 0.5 log units of activity compared to these two analogs.
Alkylation of the primary sulfonamide resulted in a similar loss of activity, although secondary
(NEU-2124) and tertiary (NEU-2118) sulfonamides were better tolerated than the excision of
the sulfonamide moiety altogether. Re-introduction of the olefin substituent at R3 (as in NEU-
4391 and NEU-4405) predictably resulted in improved potency in the case of NEU-4391,
although this came at the cost of increased clogP. Incorporation of the benzyl piperidine moi-
ety of NEU-4893 led to decreased activity.
Fig 3. General scheme for synthesis of sulfonamide replacements and construction of substituted isatin core. Reagents and reaction conditions:
a) Aryl halide, hydrazine monohydrate; 120˚C, 12 h (52–86%). b) Isatin, methanol; RT, 12 h (10–100%). c) 4-Bromoisatin, boronic acid pinacol ester,
K2CO3, Pd(PPh3)4; 100˚C, 12 h (66%).
https://doi.org/10.1371/journal.pntd.0007129.g003
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The absorption, distribution, metabolism, and excretion (ADME) properties of the sulfon-
amide replacement analogs were also assessed (S1 Table). In general, the aqueous solubility of
these compounds is low, with only two (NEU-2124 and NEU-4893) achieving a solubility
Fig 4. T. b. brucei activity of hesperadin and synthetic scheme for synthesis of NEU-4893. Reagents and reaction
conditions: a) Piperidine, TEA, AcOH, NaHB(OAc)3, DCM; RT, 12 h (85%). b) Boc-NH-NH2, NaOtBu, Pd2(dba)3, XPhos,
dioxane; μw, 150˚C, 2 h (74%). c) 4M HCl in dioxane; RT, 3 h (74%). d) NaOtBu, isatin, MeOH; RT-50˚C, 48 h (28%).
https://doi.org/10.1371/journal.pntd.0007129.g004
Table 3. Potency, LLE, and toxicity data for sulfonamide replacement analogs.
R3 R4 T.b.b. pEC50 T.b.b. LLE MRC5 pTC50
NEU-1183� -CHC(CH3)2 4-SO2NH2 7.6 5.3 <4.3
NEU-2114 H 4-OCH3 5.0 2.1 <4.3
NEU-2115 H 4-SO2NH2 5.9 4.2 <4.3
NEU-2116 H n/a 4.9 1.8 <4.3
NEU-2117 H 3,5-dichloro <4.4 0.12 <4.3
NEU-2118 H 4-SO2NMe2 5.8 3.6 <4.3
NEU-2124 H 4-SO2NHMe 5.3 3.4 <4.3
NEU-4391 -CHC(CH3)2 4-SO2NHMe 6.8 3.5 <4.3
NEU-4405 -CHC(CH3)2 4-SO2NMe2 5.3 1.8 <4.3
NEU-4893 H 4-CH2-piperidine 5.0 1.5 <4.3
�Data from original HTS [13]. All experimental error within ±0.08 log units.
https://doi.org/10.1371/journal.pntd.0007129.t003
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above 10 μM. Apart from NEU-2116, human liver microsome (HLM) clearance is low for this
cluster. However, rat hepatocyte clearance shows significantly higher variability across the
series, suggesting that mechanisms other than metabolism by CYPs may be involved in clear-
ance. Table 4 shows the ADME profile of two compounds of interest, NEU-4893 and NEU-
4391. NEU-4893 shows the best overall ADME profile of the sulfonamide replacement ana-
logs, but was inactive against T. brucei and for this reason was not pursued further. NEU-4391
showed sub-micromolar activity against T. brucei and had a reasonable ADME profile, aside
from high rat hepatocyte clearance.
Of the active compounds for which ADME data was available, NEU-4391 displayed the
best combination of potency and favorable ADME properties. We therefore progressed this
compound to mouse pharmacokinetic (PK) studies using an IP dose of 10 mg/kg (Fig 6). The
concentration of NEU-4391 in blood is represented in Fig 6A, with a Cmax of 50.1 ng/ml
Fig 5. General structure of analogs presented in Table 3.
https://doi.org/10.1371/journal.pntd.0007129.g005
Table 4. ADME profile of NEU-4893.
Targeted Value NEU-4893 NEU-4391
clogP �3 3.5 3.3
LogD (7.4) �2 2.2 nd
Aq sol (μM) >10 26 4
HLM Clint (μL/min/mg) <9 <3 8.6
Rat Hepatocyte Clint (μL/min/106 cells) <5 148 103
PPB (%) �95 90 >96
Values that meet the target are shaded green, those in an intermediate range are shaded yellow, and those that are
well outside the target value are shaded red.
https://doi.org/10.1371/journal.pntd.0007129.t004
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(0.130 μM) (S2 Table). This concentration is within two-fold of the EC50 of NEU-4391
(0.084 μM) and is unlikely to produce a therapeutic effect in vivo. Additionally, the blood and
brain concentrations of NEU-4391 were measured in a separate experiment (Fig 6B). These
results show that the concentration of NEU-4391 in the brain was below the limit of detection
for all time points (S3 Table). The combined PK results clearly indicate that NEU-4391 is
unlikely to be an effective therapeutic for either stage 1 or stage 2 HAT.
Discussion
The modest potency and suboptimal ADME-PK properties suggest that this cluster of isatins is
unsuitable for further development as anti-HAT agents. Although we discovered a compound,
NEU-4893, with an improved ADME profile over the original HTS hits, this compound lost
significant activity against T. brucei (approximately 2.5 log units as compared to NEU-1183).
The compound with the best combination of potency and ADME parameters, NEU-4391, was
progressed to in vivo PK studies, but both blood and brain concentrations were too low to war-
rant further progression.
Given our success with parasite cross-screening campaigns in the past [17], a selection of
the compounds synthesized were also tested against the related parasites T. cruzi, the causative
agent of Chagas disease and L. donovani, one of the causative agents of visceral leishmaniasis
(S3 Table). We have also previously observed activity against S. mansoni, one of the causative
agents of schistosomiasis, in compounds derived from other HTS clusters; we therefore tested
a selection of isatin derivatives against S. mansoni (S5 Table). These compounds did not show
activity against either T. cruzi or L. donovani, apart from the weak activity of NEU-4391 and
NEU-1183 against T. cruzi (pEC50 = 5.65 and 6.14, respectively). NEU-1183, -2118, and -2124
showed moderate and variable activity against S. mansoni adults and/or post-infective larvae
(somules), but based on the overall results this cluster did not warrant further investigation as
anti-schistosomal agents. We report these results in the interest of informing others who may
be working on optimization programs based on our initially-reported HTS results.
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